Table 3 Main AEs related to cannabis use during pregnancy in women and fetus and/or neonates.
All (N = 242 pregnancies) | Cannabis ± tobacco (N = 148 pregnancies) | Cannabis + other psychoactive substances/medicinal products (N = 94 pregnancies) | p* | |
|---|---|---|---|---|
In women | ||||
Psychiatric | 140 (57.9%) | 96 (64.9%) | 44 (46.8%) | 0.006 |
Use disorder | 123 (50.8%) | 89 (60.1%) | 39 (41.5%) | 0.007 |
Dependence | 79 (32.6%) | 54 (36.5%) | 25 (26.6%) | 0.11 |
Abuse | 26 (10.7%) | 21 (14.2%) | 5 (5.3%) | 0.03 |
Problematic use | 16 (6.6%) | 6 (4.0%) | 5 (5.3%) | 0.89 |
Threat of premature birth | 18 (7.4%) | 13 (8.8%) | 5 (5.3%) | 0.32 |
Premature rupture of membranes | 15 (6.2%) | 12 (8.1%) | 3 (3.2%) | 0.12 |
In fetus and/or neonates | ||||
IUGR in fetus and/or neonate | 78 (32.2%) | 48 (32.4%) | 30 (31.9%) | 0.93 |
Prematurity | 50 (20.7%) | 32 (21.6%) | 18 (19.1%) | 0.64 |
Withdrawal syndrome | 45 (18.6%) | 11 (8.1%) | 34 (36.2%) | < 0.001 |
Fetal heart rhythm disorders | 34 (14.0%) | 25 (16.9%) | 10 (10.6%) | 0.18 |
Congenital malformations in fetus and/or neonate | 19 (7.8%) | 12 (8.1%) | 7 (7.4%) | 0.85 |
Apgar ≤ 7 at 1 min | 18 (7.4%) | 11 (7.4%) | 7 (7.4%) | 1.0 |
Respiratory failure | 16 (6.6%) | 7 (4.7%) | 9 (9.6%) | 0.14 |
Intrauterine fetal death, neonatal death | 6 (2.5%) | 4 (2.7%) | 2 (2.1%) | 0.57 |
